Merck & Co.'s conference call revealed strong performance in 2019, with impressive revenue and non-GAAP EPS growth, driven particularly by the success of products like KEYTRUDA. The discussion of spinning off NewCo, which includes Women's Health and biosimilar products, appears to be a strategic restructuring to focus Merck on its high-growth areas like oncology. Despite potential initial concerns about the concentration risk with KEYTRUDA, management communicated confidence in their diversified growth strategy across oncology, vaccines, and animal health. Overall, the upbeat tone on operational efficiencies, debt capacity for business development, and commitment to R&D investment suggests a positive short-term outlook for the stock. 

[1]